New York, NY -- (SBWIRE) -- 04/12/2021 -- The global Hypertrophic Cardiomyopathy Therapeutics Market valued at USD 1.20 Billion in 2019 and is expected to reach USD 1.42 billion by the year 2027, at a CAGR of 2.1%. Hypertrophic cardiomyopathy (HCM) alters the functioning of the heart. Increasing prevalence of cardiovascular disorders, lifestyle habits like smoking and consumption of alcohol, obesity, and growth in the geriatric populations are the factors driving the growth of the market. However, the high-cost expenditure of treatment is restraining the market. According to the report, the World Health Organization (WHO) estimated that 17.9 million people died from cardiovascular diseases in the year 2016, which includes approximately 31% of all global deaths. According to the WHO, in 2016, more than 1.9 billion adults aged 18 years and older were overweight. Regionally, in Africa, the number of overweight children under five has increased by nearly 50% since 2000. Approximately half of the children under five who were overweight or obese in 2018 lived in Asia. The prevalence of obesity among children and adolescents aged 5-19 has risen dramatically. According to Canadian Community Health Survey, in 2018, nearly 63.1% of Canadian adults were either obese or overweight, in which approximately 26.8%, i.e., 7.3 million adults, were obese and another 9.9 million, i.e., 36.3% of Canadian adults were overweight. In 2019 approximately 35% of Americans were obese or overweight in the United States.

Asia Pacific region is likely to increase the market growth due to factors like an increase in the patient population, lifestyle habits like smoking and consumption of alcohol and, rise in the geriatric population, etc.

Get a FREE Report Sample with Table of Contents and Figures @ https://www.reportsanddata.com/sample-enquiry-form/2711

Further key findings from the report suggest

In the year 2019, Correvio Pharma had resubmitted the New Drug Application (NDA) for Brinavess (vernakalant hydrochloride) for the treatment of cardiac arrhythmias to the Food and Drug Administration. But the FDA issued a CRL letter to Correvio Pharma and rejected Brinavess (vernakalant hydrochloride) as it was seen that the drug had prolonged atrial refractoriness and slowed the impulse conduction in a rate-dependent fashion, but the data provided in the application did not provide reassurance of the safety.
The NYIT College of Osteopathic Medicine (NYITCOM) researchers, offered a new treatment for patients with beta-blocker intolerance, here T3 (thyroid hormone therapy) was used in the treatment. It is an effective method for managing cardiovascular disorders, and showed better contraction and relaxation of the heart, and was found to be a better treatment for patients.
Strokes are one of the causes of hypertrophic cardiomyopathy. In February 2020, the FDA had approved a clinical trial that on Abbott's Amplatzer Amulet, a stroke prevention device it was found to be more beneficial than the new class of blood thinners that are currently used in the treatment. It involves a minimally invasive procedure used for patients with atrial fibrillation. It is an effective non-prescription drug alternative for patients with arterial fibrillation who are at an increased risk for ischemic stroke.
Medtronicin January  2020, had announced that it had received the CE Mark for its Cobalt and Crome portfolio of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy-defibrillators (CRT-D).ICDs are used to monitor heart rhythms and supply proper therapy to correct heart rates that are too fast that lead to sudden cardiac arrest. CRT-Ds is a treatment option for some individuals with heart failure; it sends small electrical impulses to the lower chambers of the heart to support them beat in more synchronized patterns and to reduce arrhythmia symptoms.
Merck in the year 2019 announced an acquisition of ArQule for arround USD 2.7 billion. This acquisition had strengthened Merck's pipeline it and also included ARQ 531 for the treatment of B-cell malignancies.
By Drugs segment, the antiarrhythmic drugs have obtained the largest share of about 36.4% in the year 2019, due to the rise in the incidences of cardiac arrhythmias and also due to the lifestyle factors like smoking and consumption of alcohol
On the basis of devices defibrillators accounted for USD 598.3 million for the year 2019.
AstraZeneca, Merck, Pfizer, Sanofi, Gilead Sciences, Novartis, Teva Pharmaceutical, Correvio Pharma Industries, Abbot, Lupin limited are the key players in the Hypertrophic Cardiomyopathy Therapeutics market.

For the purpose of this purpose, Reports and Data have segmented the Hypertrophic Cardiomyopathy Therapeutics market on the basis of drugs, devices, end use, and region.

Drugs Outlook (Revenue in Million USD; (2017–2027)

Antiarrhythmic Agents
Anticoagulants
Beta-Adrenergic Blocking Agents
Calcium Channel Blockers
Others

Devices Outlook (Revenue in Million USD; (2017–2027)

Defibrillators
Pacemakers
Other Medical Devices

End Use Outlook (Revenue in Million USD; (2017–2027)

Hospitals
Clinics
Others

Browse Complete Report "Hypertrophic Cardiomyopathy Therapeutics Market" @ https://www.reportsanddata.com/report-detail/hypertrophic-cardiomyopathy-therapeutics-market

Regional Outlook (Revenue in USD Billion; 2017–2027)

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

TOC -
Chapter 1. Market Synopsis

    1.1. Market Definition

    1.2. Research Scope & Premise

    1.3. Methodology

    1.4. Market Estimation Distribution Channel

Chapter 2. Executive Summary

    2.1. Summary Snapshot, 2017 – 2027

Chapter 3. Indicative Metrics

Chapter 4. COVID 19 impact assessment

    4.1. Healthcare Hypertrophic Cardiomyopathy Therapeutics Industry Outlook

………..

Chapter 10. Competitive Landscape

    10.1. Market Revenue Share by Manufacturers

    10.2. Mergers & Acquisitions

    10.3. Strategy Benchmarking

            10.3.1. Partnership & Agreement

            10.3.2. New Products Development

            10.3.3. Mergers & Acquisitions

            10.3.4. Investment & Expansion

    10.4. Vendor Landscape

Chapter 11. Company Profiles

    11.1. AstraZeneca

            11.1.1. Company Overview

            11.1.2. Financial Insights

            11.1.3. Products Offered

            11.1.4. Strategic Initiatives

    11.2. Merck

             11.2.1. Company Overview

             11.2.2. Financial Insights

             11.2.3. Products Offered

             11.2.4. Strategic Initiatives

    11.3. AG Pfizer

             11.3.1. Company Overview

             11.3.2. Financial Insights

             11.3.3. Products Offered

             11.3.4. Strategic Initiatives

    11.4. Sanofi

            11.4.1. Company Overview

            11.4.2. Financial Insights

            11.4.3. Products Offered

            11.4.4. Strategic Initiatives

    11.5. Gilead Sciences

             11.5.1. Company Overview

             11.5.2. Financial Insights

             11.5.3. Products Offered

             11.5.4. Strategic Initiatives

Continued……….

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/2711

The report is a qualitative and quantitative research study that offers key insights into the latest strategic steps and tactics undertaken by the industry players to gain a robust footing in the market. The report further offers strategic recommendations to the new and emerging players and established companies to help them overcome the barriers of the industry. The report also covers a comprehensive SWOT analysis and Porter's Five Forces analysis to offer a better understanding of the Hypertrophic Cardiomyopathy Therapeutics market and its competitive landscape.

Browse Related Reports –

Refractories Market Analysis

Intravenous Immunoglobulin (IVIG) Market Trends

Stainless Steel Forging Market Growth

Genome Editing Market Demand

Foot and Mouth Disease (FMD) Vaccine Market Size

Arthroscopy Market Share

Thank you for reading our report. For further inquiries or queries about customization, please get in touch with us. Our team will ensure the report you get is best suited to your needs.

About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:

John W

Head of Business Development

Reports And Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com